Eli Lilly
FDA Approves Agilent Technologies CDx for Breast Cancer Drug Verzenio
The CDx is the first FDA-approved immunohistochemistry assay to measure Ki-67 protein expression in the context of treatment with Eli Lilly's abemaciclib (Verzenio).
Pair of Studies Show Plasma Protein Marker Could Aid Alzheimer's Disease Diagnosis
Washington University researchers and a team including scientists from Eli Lilly independently identified a modified form of tau as a promising Alzheimer's marker.
FDA Grants Emergency Use Authorization for Eli Lilly, Sandia National Labs Coronavirus PCR Tests
Both of the RT-PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in a variety of swab samples and other specimens.
Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
Premium
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
Thermo Fisher Scientific, Eli Lilly to Develop CDx for RET Inhibitor
The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.